Strong Competition Expected as Generics Eye Axiron Market Share; Lowering FVE to AUD 0.40 per Share
Acrux reported fiscal 2016 net profit after tax of AUD 13 million on royalty revenue of AUD 28.6 million, down 53% and 60%, respectively. These were broadly as expected given the release of Axiron sales data by Eli Lilly in July.Unfortunately, the result was overshadowed by the surprise decision from the United States District Court for the Southern District of Indiana. The court held that the Axiron formulation and axilla (site of application) patents granted were invalid, and that the applica...
Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.